ArticleBMJ open2026
Clinical efficacy and neurophysiological changes associated with combined transcutaneous auricular vagus nerve stimulation and repetitive transcranial magnetic stimulation in chronic insomnia disorder: protocol for a randomised controlled trial.
Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionChronic insomnia disorder (CID) is a prevalent condition associated with substantial impairment in quality of life and increased risk of comorbidities. Emerging evidence suggests that CID is associated with autonomic dysregulation and cortical hyperarousal, consistent with the hyperarousal model. Neuromodulation techniques, including transcutaneous auricular vagus nerve stimulation (taVNS) and repetitive transcranial magnetic stimulation (rTMS), have shown therapeutic potential. However, most previous studies have focused on single-modality interventions and whether a combined approach provides incremental clinical or neurophysiological benefits remains unclear. This study aims to evaluate the incremental clinical benefit of combined taVNS and rTMS relative to either active component alone and to explore associated neurophysiological changes. METHODS AND ANALYSIS: This study is a randomised, double-blind, three-arm parallel-group controlled trial. A total of 90 eligible participants will be randomly assigned to one of three groups: Group A (taVNS+rTMS), Group B (sham taVNS+rTMS) or Group C (taVNS+sham rTMS). The intervention will be administered over 2 weeks (10 sessions) followed by a 12-week follow-up period. The primary outcome is the Pittsburgh Sleep Quality Index (PSQI) assessed post-intervention (T1) and at the 4-week (T2) and 12-week (T3) follow-ups. Secondary outcomes include electroencephalography, functional near-infrared spectroscopy, resting motor threshold, heart rate variability and sleep/daytime function-related scales. A baseline-adjusted mixed model for repeated measures will be used for the longitudinal analysis of PSQI. At the primary efficacy time point (T1), the two prespecified primary treatment contrasts will compare Group A with Group B and Group A with Group C. ETHICS AND DISSEMINATION: This study has been approved by the Ethics Committee of Guangdong Provincial Hospital of Chinese Medicine (approval number: ZF2025-268-02). Written informed consent will be obtained from all participants prior to enrolment. The results of this study will be disseminated through peer-reviewed publications and academic conferences.
trial registrationChiCTR2600120955; registered on 23 March 2026.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.